Laura Zitella on Third-Line Treatment Considerations in Diffuse Large B-Cell Lymphoma
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses third-line treatment options for patients with diffuse large b-cell lymphoma.
Combination chemotherapy with rituximab (Rituxan), known as R-CHOP, has been the standard of practice for diffuse large B-cell lymphoma for many years and is commonly used in many patients, explains Laura Zitella, MS, RN, ACNP-BC, AOCN. However, patients who do not respond to this chemoimmunotherapy treatment may progress to CAR T-cell therapy and other options in the second-line and beyond setting, such as loncastuximab tesirine (Zynlonta).
Zitella, a nurse practitioner at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, and associate clinical professor at UCSF school of nursing, also recently presented at PER®s Onco-Nurse Academy about safely administering Integrating Novel Therapies Across the DLBCL Care Spectrum.
In an interview with Oncology Nursing News®, Zitella highlights what treatment options exist for patients whose disease progresses beyond CAR T-cell therapy options, and the important considerations nurses should keep in mind with the available third-line agents.